Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Other Working Capital Changes (2023 - 2025)

Mangoceuticals' Other Working Capital Changes history spans 3 years, with the latest figure at -$21251.0 for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 152.37% to -$21251.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$74046.0, a 107.53% decrease, with the full-year FY2025 number at -$74046.0, down 1022.76% from a year prior.
  • Other Working Capital Changes hit -$21251.0 in Q4 2025 for Mangoceuticals, down from -$17950.0 in the prior quarter.
  • Over the last five years, Other Working Capital Changes for MGRX hit a ceiling of $283333.0 in Q1 2024 and a floor of -$129363.0 in Q4 2023.
  • Historically, Other Working Capital Changes has averaged $42483.7 across 3 years, with a median of $1140.5 in 2023.
  • Biggest five-year swings in Other Working Capital Changes: soared 1350.76% in 2024 and later tumbled 153.85% in 2025.
  • Tracing MGRX's Other Working Capital Changes over 3 years: stood at -$129363.0 in 2023, then surged by 131.37% to $40577.0 in 2024, then plummeted by 152.37% to -$21251.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for MGRX at -$21251.0 in Q4 2025, -$17950.0 in Q3 2025, and -$17596.0 in Q2 2025.